• Medicine
  • Published 2016

Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31

@inproceedings{Paik2016BenefitFA,
  title={Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31},
  author={S. Paik and Chungyeul Kim and Jong-Hyeon Jeong and Ce Geyer and Edward H. Romond and Olga Mej{\'i}a-Mej{\'i}a and Eleftherios P. Mamounas and D. Lawrence Wickerham and J. P. Costantino and Norman Wolmark},
  year={2016}
}
511 Background: Trastuzumab is a humanized monoclonal antibody targeted to HER2 protein and currently indicated for HER2-positive breast cancer defined by overexpression of HER2 protein (3+ IHC staining by HercepTest™) or HER2 gene amplification (HER2/CEP17 ratio over 2 by PathVysion® FISH assay). These criteria were determined for advanced disease but have not been formally tested in the adjuvant setting. We examined these tests’ ability to predict benefit from adjuvant trastuzumab in NSABP… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.

  • Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • 2010
VIEW 2 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND